The FDA Approves a Generic form of Copaxone®
Thursday, April 16, 2015
The U.S. Food and Drug Administration has approved a generic form of Copaxone® (glatiramer acetate), called Glatopa™ (Sandoz, a Novartis company, developed with Momenta) as a disease-modifying therapy for people with relapsing forms of MS, including those who have experienced a first clinical episode and have MRI features consistent with MS. The generic medication is a 20mg dose injected subcutaneously daily. This approval means that the manufacturer provided evidence that this generic medication is equivalent to the brand-name drug (Copaxone®). There is no information yet on when Glatopa will be available by prescription in the United States or its cost.
